Annals of Surgical Oncology

, Volume 25, Issue 12, pp 3701–3708 | Cite as

BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study

  • Claudia Marchetti
  • Rossella De Leo
  • Angela Musella
  • Marco D’Indinosante
  • Ettore Capoluongo
  • Angelo Minucci
  • Pierluigi Benedetti Panici
  • Giovanni Scambia
  • Anna FagottiEmail author
Gynecologic Oncology



The aim of this study was to assess the correlation between BRCA mutation status and disease presentation, treatment strategy, and survival in a multicenter series of recurrent high-grade serous ovarian cancer (HGSOC) women.


A consecutive series of recurrent HGSOC patients with partially or fully platinum-sensitive disease admitted to the Gynecologic Oncology Units of the Catholic University of the Sacred Heart and Sapienza University of Rome. Main eligibility criteria were known BRCA 1/2 germline mutation status and a minimum follow-up period from recurrence of at least 6 months.


Overall, 126 patients met the eligibility criteria, of whom 76 (60%) were BRCA wild-type (BRCAwt) and 50 (40%) were BRCA 1/2 germline mutation carriers (BRCAmut). Among the latter, 37 (74%) patients presented with BRCA1 mutation, and 13 (26%) presented with BRCA2. No differences were found regarding patterns of disease presentation between BRCAwt and BRCAmut women. BRCAmut patients had the best post-recurrence survival (PRS) regardless of having received secondary cytoreductive surgery (SCS) or not, with a 5-year PRS of 73% in non-resected women versus 78% in resected women (p = 0.558). Conversely, BRCAwt patients who underwent complete SCS had a significantly longer PRS compared with BRCAwt patients who did not receive surgery (5-year PRS of 54% vs. 42%; p = 0.048).


Recurrent ovarian cancer BRCAmut patients have the best prognosis regardless of SCS, whereas PRS in BRCAwt women can improve when complete SCS is performed. The identification and incorporation of predictive biomarkers such as BRCA status to tailor the medical and surgical approach is paramount to the success of recurrent HGSOC treatments.





Claudia Marchetti, Rossella De Leo, Angela Musella, Marco D’Indinosante, Ettore Capoluongo, Angelo Minucci, Pierluigi Benedetti Panici, Giovanni Scambia, and Anna Fagotti declare no conflicts of interest.

Supplementary material

10434_2018_6700_MOESM1_ESM.doc (43 kb)
Supplementary material 1 (DOC 43 kb)
10434_2018_6700_MOESM2_ESM.jpg (31 kb)
Supplementary material 2 (JPEG 30 kb)


  1. 1.
    Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced- stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013; 10: 211–224.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011; 22:1127–1132.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Petrillo M, Marchetti C, De Leo R, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017; 217(3): 334.e1–334.e9.CrossRefGoogle Scholar
  5. 5.
    Bookman MA, Tyczynski JE, Espirito JL,Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol. 2017;146(1): 58–63.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lorusso D, Scambia G, Pignata S, et al. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol. 2016; 27(3):487–93.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract. 2016;3:3.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75(3–4):152–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Fanfani F, Monterossi G, Fagotti A, et al. Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2015;22(2):649–54.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer. 2006;42(14):2296–302.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zielinski CC, Pinto C. AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open. ESMO Open. 2016;1(4):e000080.CrossRefGoogle Scholar
  12. 12.
    Minucci A, Scambia G, Santonocito C, et al. Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review. Expert Rev Mol Diagn. 2015;15(10):1383–403.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Balabanski L, Antov G, Dimova I, et al. Next-generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects. Mol Clin Oncol. 2014;2:435–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Concolino P, Rizza R, Hackmann K, et al. Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome. Breast Cancer Res Treat. 2017;164(2):497–503.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Concolino P, Costella A, Minucci A, et al. A preliminary quality control (QC) for next-generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations. Clin Chim Acta. 2014;437:72–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Capoluongo E, Ellison G, López-Guerrero JA, et al. Guidance statement on BRCA1/2 tumor testing in ovarian cancer patients. Semin Oncol. 2017;44(3):187–197.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Minucci A, De Paolis E, Concolino P, et al. Competitive PCR-High Resolution Melting Analysis (C-PCR-HRMA) for large genomic rearrangements (LGRs) detection: a new approach to assess quantitative status of BRCA1 gene in a reference laboratory. Clin Chim Acta. 2017;470:83–92.CrossRefGoogle Scholar
  18. 18.
    Badoer C, Garrec C, Goossens D, et al. Performance of multiplicom’s BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples. Oncotarget. 2016;7(49):81357–81366.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Capoluongo E. BRCA to the future: towards best testing practice in the era of personalised healthcare. Eur J Hum Genet. 2016;24 Suppl 1:S1-2.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    BRCA Germline I Reference Standard gDNA. Available at:
  21. 21.
    Petrillo M, Nero C, Amadio G, Gallo D, Fagotti A, Scambia G. Targeting the hallmarks of ovarian cancer: the big picture. Gynecol Oncol. 2016;142(1):176–183.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fanfani F, Fagotti A, Gallotta V, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol. 2010;116(3):497–501.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007; 14(3):1136–42.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Manci N, Bellati F, Muzii L, et al. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data. Ann Surg Oncol. 2006; 13(12):1717–23.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol. 2012;2012:613980.Google Scholar
  26. 26.
    Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017; 35 Suppl: abstract no. 5501.Google Scholar
  27. 27.
    Harter P, Du Bois A, Hahmann M, et al. Suregery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–10.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Tian WJ, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20:463–466.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530–5536.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Concolino P, Rizza R, Hackmann K, et al. Identification and characterization of a new BRCA2 Rearrangement in an Italian family with hereditary breast and ovarian cancer syndrome. Mol Diagn Ther. 2017;21(5):539–545.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wu X, Wu L, Kong B, et al. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. Int J Gynecol Cancer. 2017;27(8):1650–1657.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Eoh KJ, Kim JE, Park HS, et al. Detection of Germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1/2. Cancer Res Treat. 2018;50(3):917–925.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018
Corrected ​publication ​August/2018

Authors and Affiliations

  • Claudia Marchetti
    • 1
  • Rossella De Leo
    • 2
  • Angela Musella
    • 1
  • Marco D’Indinosante
    • 2
  • Ettore Capoluongo
    • 3
  • Angelo Minucci
    • 3
  • Pierluigi Benedetti Panici
    • 1
  • Giovanni Scambia
    • 2
  • Anna Fagotti
    • 2
    Email author
  1. 1.Department of Gynecological-Obstetrical Sciences and Urological SciencesSapienza University of RomeRomeItaly
  2. 2.Department of Woman and Child Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCSUniversità Cattolica del Sacro CuoreRomaItalia
  3. 3.Laboratory of Clinical Molecular and Personalized Diagnostics, Fondazione Policlinico Universitario A. Gemelli, IRCCSUniversità Cattolica del Sacro CuoreRomaItalia

Personalised recommendations